DPH2 is a biomarker associated with cell death, immunity and prognosis based on pan-cancer analysis
DPH2 has potential as a novel prognostic biomarker that may significantly impact tumor onset and progression. Consequently, DPH2 could serve as a target for new cancer treatments.
Authors
- Maolin Xiao (ORCID: https://orcid.org/0000-0003-2864-7394)
- Liangdong Song
- Shuai Su (ORCID: https://orcid.org/0000-0002-1648-0817)
- Delin Wang (ORCID: https://orcid.org/0000-0003-0689-3199)
- Xiangbiao He
Institutions
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-02-10
- DOI
- https://doi.org/10.1007/s12672-025-01924-6
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Chongqing Science and Technology Foundation